HealthcareLarge capRs 115,700 crRs 119.7 cr traded a dayManufacturingHealthcarePharmaceuticals
Close on 2026-08-21
1,432.20
−0.40%
52-week range51% of the way up
1,192.401,663.60
Market cap
115,700 cr
P/E (TTM)
34.5×
industry 44×
EPS (TTM)
41.54
Revenue YoY
+2.3%
Q1 FY27
Profit YoY
-39.2%
Net margin
11.0%
-7.5pt vs a year ago
Growth trend
+5.1pt
vs last quarter’s YoY
1 month
+2.8%
Below 52w high
16.2%
RSI (14)
32
Daily swing
1.4%
average true range
Volume
0.8×
vs 20-day average
Traded
Rs 120 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
1 week
−1.23%
1 month
+2.81%
3 months
+1.04%
6 months
+5.46%
1 year
−8.73%
The read
written from the numbers on this page
The evidence is mixed4 supporting, 3 against, 2 worth knowing
Supporting
trading 3% above its 200-day average
5 independent kinds of evidence agree today, which is uncommon
priced at 34× earnings against an industry median of 44× — 22% below its peers
futures show a long buildup — the move is being funded by new positions
Against
down 9% over twelve months
1 of the scans it matches has historically underperformed the market
net margin has narrowed from 17.8% to 11.0% across four quarters
Worth knowing
the 50-day and 200-day averages disagree, which usually means a turn in progress rather than a trend to lean on
revenue grew 2% year on year in the quarter ending 2026-06-30
CIPLA sits in Manufacturing, Healthcare, Pharmaceuticals — worth checking whether the whole group is moving together or whether this name is doing it alone.
What would change this read: a close below 1,389, its 200-day average; open interest reversing while price keeps going.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
read from the filings, with the figure behind every line
Working
Nothing in the filings stands out either way.
Needs watching3
Net margin moved from 18.6% to 11.0%.
18.6%11.0%
Net profit -39.2% year on year, Rs 1,292 cr to Rs 786 cr.
-39.2%Rs 1,292 crRs 786 cr
Profit grew slower than revenue, -39.2% against +2.3%.
-39.2%+2.3%
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.
How it has performed
price return over each window, measured against zero
What the scans say today
6 of 47 matched on 2026-08-21
CIPLA matches 6 of the 47 scans today, across 5 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
CIPLA trades at 34× trailing earnings, above its median of 24× over this window — 45% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Order win filings were typically +0.20pt vs the market over the next 5 sessions (n=408) · Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093) · Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 2% against the same quarter a year earlier
net margin widened from 8.3% to 11.0%
Going against it
profit dropped 39% year on year
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
7,119
1,082
786
9.77
11.0%
Q4 FY26
2026-03-31 · consolidated
6,541
707
543
6.87
8.3%
Q3 FY26
2025-12-31 · consolidated
7,074
893
674
8.37
9.5%
Q2 FY26
2025-09-30 · consolidated
7,589
1,854
1,353
16.73
17.8%
Q1 FY26
2025-06-30 · consolidated
6,957
1,770
1,292
16.07
18.6%
Q4 FY25
2025-03-31 · consolidated
6,730
1,504
1,214
15.13
18.0%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average-0.3%
Versus 200-day average+3.1%
Below 52-week high-13.9%
Above 52-week low+20.1%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)32.2
Higher closes in last 51 of 5
Six-month return+5.46%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)1.38%
Volume versus 20-day0.8x
Median daily turnoverRs 119.7 cr
Derivatives
near expiry 2026-08-25 · 2026-08-20
Long Buildup
Price up, open interest up. New buyers are arriving rather than old sellers leaving — the move is being funded, not squeezed.
Futures basis versus spot-0.18%
Open interest change+1.1%
Put / call ratio0.60
Put wall (support)1,350
Call wall (resistance)1,500
Max pain1,450
How to read this
Open interest is contracts still open, so a rise means new positions and a fall means positions closing. Combined with price direction that gives the state on the left. The walls are the strikes carrying the most open interest near expiry — levels other people are watching, not levels the price is obliged to respect. A future below spot means sellers are paying to be short.
Peers
Healthcare · 67 classified companies
CIPLA trades at 34.5× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — cheaper than them, by 22%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.
Session
Scans
Which
2026-08-20
1
Rising without the drama
2026-08-19
3
Back above the 200-day line, Uptrend taking a breather, Oversold, but trend intact
2026-08-18
2
Uptrend taking a breather, Inside bar — quieter than yesterday